This bill reauthorizes and significantly expands a federal demonstration program focused on sickle cell disease. It extends the program's funding through fiscal years 2025 to 2029 , substantially increasing the annual allocation from $4.455 million to $8.205 million . The legislation broadens the program's focus to explicitly include the prevention and treatment of complications of sickle cell disease , alongside the disease itself. It also diversifies the funding mechanisms, allowing for the use of grants and cooperative agreements in addition to contracts for program implementation. Furthermore, the bill includes a Sense of Congress emphasizing the need for continued research into the causes and cures for heritable blood disorders, including sickle cell disease.